SLC5A2 and heart failure: It is well established that improving glycaemic control result in improved cardiovascular outcomes, and indeed worsens CV morbidities and mortality in certain patient populations.[5,6] Furthermore, it remains a subject of ongoing debate as to the comparative efficacy of various drugs within the SGLT2 family in reducing hard cardiovascular endpoints including heart failure.[7] Additionally, despite accumulating evidence pointing to their association with risk of genitourinary tract infections, the magnitude of association with each individual drug remains unknown.